Squarepoint Ops LLC Zymeworks Inc. Transaction History

Squarepoint Ops LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$4.82 - $7.7 $1.13 Million - $1.81 Million	235,285 New	235,285 $1.25 Million
Q3 2021 Nov 15, 2021	SELL	$27.35 - $37.28 $792,466 - $1.08 Million	-28,975 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$26.5 - $38.23 $503,076 - $725,758	18,984 Added 190.01%	28,975 $1.01 Million
Q1 2021 May 17, 2021	BUY	$29.83 - $56.81 $298,031 - $567,588	9,991 New	9,991 $316,000
Q4 2020 Feb 16, 2021	SELL	$39.12 - $54.99 $344,490 - $484,241	-8,806 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$29.21 - $46.58 $246,999 - $393,880	-8,456 Reduced 48.99%	8,806 $410,000
Q2 2020 Aug 14, 2020	BUY	$33.67 - $40.0 $126,127 - $149,840	3,746 Added 27.72%	17,262 $623,000
Q1 2020 May 15, 2020	BUY	$24.28 - $49.8 $46,520 - $95,416	1,916 Added 16.52%	13,516 $479,000
Q4 2019 Feb 14, 2020	BUY	$24.84 - $45.46 $288,144 - $527,336	11,600 New	11,600 $527,000
Q4 2018 Feb 14, 2019	SELL	$10.95 - $15.44 $329,562 - $464,697	-30,097 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$12.21 - $16.61 $104,200 - $141,749	-8,534 Reduced 22.09%	30,097 $473,000
Q2 2018 Aug 14, 2018	BUY	$11.13 - $21.86 $429,963 - $844,473	38,631 New	38,631 $571,000

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $903M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

Stay updated on Squarepoint Ops LLC with notifications on news.